A new publication involving growth hormone-releasing peptide-2, also known as GHRP-2, appeared on September 11, 2026. The paper, titled "Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests," was published in Endocrine Journal.
The publication addresses the use of corticotropin-releasing hormone and GHRP-2 stimulation tests in a diagnostic context. It focuses on distinguishing hypothalamic causes of adrenal insufficiency from pituitary causes.
GHRP-2 remains classified as an unapproved compound intended for research use. This publication is listed in PubMed under ID 42732957 and is available through the journal's official channels.
No specific findings, outcomes, or conclusions from the study are detailed here beyond the title and its publication venue. Readers interested in the diagnostic methodology or study details should consult the full text directly through the journal or PubMed listing.
For more background on this compound, see the linked overview page.